Roles Of Fas Ligand In Hepatocytes Infection By HBV

Objective To observe the role of FasL in hepatocytes infection by hepatitis virus B ( HBV ) ,to investigate the effect of FasL; To study the effect of soluble Fas and soluble Fas Ligand in the pathogenesis of chronic serious hepatitis B and HBV related hepotocellular carcinoma(HBV related HCC).Methods Investigation whether FasL expressing HepG2x cells induce apoptosis of Fas expressing cells was done by DNA fragmention on gel electrophesis, flow cytometric detection method (FACS), immuohistochemical staining when those cells cocultured with HepG2x cells for 48 hours. Analyze soluble Fas (sFas) and soluble Fas Ligand (sFasL) Levels with ELISA in four groups, 41 Asymptomatic HBsAg carriers ,40 cases of chronic serious hepatitis B and 42 cases of HBV related HCC ,37 healthy blood donor as control group. sFas-sFasL complements were also detected in chronic serious hepatitis B group.Results (1) FasL expression HepG2 cells could induce apoptosis of Fas expressing cells (2)The sFas and sFasL levels in chronic serious hepatitis B group both significantly increased (p<0.01), and the sFas level in HBV related HCC group significantly increased, furthermore the sFasL level decreased. (3)sFas-sFasL complements in chronic serious hepatitis B group can be detected.(4)The apoptotic rate of PBLCs in HCC by FACS was significantly higher than that in controls (p < 0.01 =.Conclusion (1) FasL expressed in hepatocytes could induce apoptosis of Fas expressing cells .(2) The method of labeled Apo2.7 antibody detecting in Situ can detect the apoptotic PBLC as a substitute for FACS. (3)For the first time, the method of detection sFas-sFasL complement in serum was established, and for the first time the complement was successfully detected in patient serum. There is significant relationship between sFas /sFasL levels and chronic serious hepatitis B/ HBV related HCC. sFas-sFasL complements level of chronic serious hepatitis B group is significantly higher than HBV related HCC group and HBsAg carrier group. Serum sFas and sFasL seemed to inhibit Fas-mediated apoptosis. They play important roles in hepatic apoptosis and necrosis, and may be used as important clue in diagnosis, differential diagnosis and therapy in chronic serious hepatitis B and HBV related HCC.